Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS: This multicenter placebo-controlled double-blind randomized phase III tri...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Moore, Kathleen N., Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A., Garcia, Yolanda, Sharma, Sudarshan K., Darus, Christopher J., Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K., Lin, Yvonne G., Pignata, Sandro
Формат: Artigo
Язык:Inglês
Опубликовано: Wolters Kluwer Health 2021
Предметы:
RAPID COMMUNICATIONS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8189598/
https://ncbi.nlm.nih.gov/pubmed/33891472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00306
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы